This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Pharmacokinetic (PK), Pharmacodynamic (PD) and Tol...
Clinical trial

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease

Read time: 2 mins
Last updated:31st Jan 2019
Identifier: NCT03708900

Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's disease.

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease
Estimated Study Start Date: January 31, 2019
Estimated Primary Completion Date: March 22, 2021
Estimated Study Completion Date: January 7, 2022

- Experimental:
LCI699 (osilodrostat)

Category Value
Date last updated at source 2018-12-14
Study type(s) Interventional
Expected enrolment 20
Study start date 2019-01-31
Estimated primary completion date 2021-03-22

View full details